MaxCyte Community

AIM:MXCT Community

1 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

AN

AnalystConsensusTarget

Consensus Narrative from 2 Analysts

SeQure Dx Acquisition And CASGEVY Will Boost Cell Therapy Prospects

Key Takeaways Acquisition of SeQure Dx and SPL portfolio expansion could drive future revenue growth through improved offerings and new clinical progressions. Strategic focus on efficiency and high-growth areas may enhance net margins and long-term profitability amid expected market growth in cell and gene therapy.

UK£5.02

FV

57.8% undervalued

17.54%

Revenue growth p.a.

0

0

4

1 day ago